

Sanyou Bio and TransRecoBio to build new ecosystem for full industry chain in China

13 May 2025 | News

Accelerating the development of novel drug formulations



Sanyou Biopharmaceuticals Co. and TransRecoBio Biotechnology Co. have signed a strategic cooperation agreement. The two companies will integrate their core strengths in antibody drug discovery and innovative formulation manufacturing, with a focus on addressing major unmet clinical needs in ophthalmology, autoimmune diseases, metabolic disorders, anti-aging, and infectious diseases.

Together, they will advance the development of cutting-edge formulations such as eye drops, topical gels, and inhalation agents, creating an end-to-end solution covering R&D, manufacturing, and commercialisation, thereby accelerating the development of novel drug formulations.

This strategic partnership pioneers a new collaborative model of "Biotech + CDMO + National-Level Platforms." Sanyou Biopharmaceuticals leverages its globally leading AI-STAL platform—a trillion-scale intelligent molecular library—to empower drug discovery. This library encompasses ten major molecule types, including full-length antibodies, single-domain antibodies, bispecifics, trispecifics, peptides, and mini-proteins, with a capacity in the tens of trillions. It can rapidly generate thousands of lead molecules, significantly shortening the drug development timeline. By combining intelligent drug screening and preclinical research, Sanyou is accelerating the translation of laboratory innovations into clinical applications.

TransRecoBio, backed by two national-level platforms—the National Key Laboratory for Large Molecule Drug Manufacturing and the National Engineering Research Center for Growth Factor Drugs and Protein Formulations—possesses leading-edge capabilities in microbial/eukaryotic protein production, BFS ophthalmic formulations, and lyophilised/injectable formulations. With advanced manufacturing facilities and a rigorous quality management system, the company ensures reliable high-quality product supply.

This strategic partnership marks a step forward for China's biopharmaceutical industry toward a fully integrated, collaborative development model. It is expected to significantly enhance the efficiency of innovative therapy R&D and industrialisation, offering more therapeutic options to patients worldwide.